for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Endo International PLC

ENDP.O

Latest Trade

5.79USD

Change

0.00(0.00%)

Volume

2,815,358

Today's Range

5.69

 - 

5.88

52 Week Range

2.08

 - 

7.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.79
Open
5.86
Volume
2,815,358
3M AVG Volume
103.44
Today's High
5.88
Today's Low
5.69
52 Week High
7.10
52 Week Low
2.08
Shares Out (MIL)
229.82
Market Cap (MIL)
1,257.09
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Endo International PLC Earnings Release

Latest Developments

More

BioSpecifics To Be Acquired By Endo Pharmaceuticals

Endo To Acquire BioSpecifics To Enhance Profitability Of Xiaflex And Qwo

Endo Announces Fill-Finish Manufacturing And Services Agreement For Novavax Covid-19 Vaccine Candidate

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Endo International PLC

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Industry

Biotechnology & Drugs

Contact Info

Minerva House, Simmonscourt Road

000 00

Ireland

+353.1.2682000

http://www.endo.com

Executive Leadership

Paul V. Campanelli

Chairman of the Board

Blaise Coleman

President, Chief Executive Officer, Director

Terrance John Coughlin

Chief Operating Officer, Executive Vice President

Patrick Barry

Executive Vice President and Chief Commercial Officer, U.S. Branded Business

Domenico Ciarico

Executive Vice President and Chief Commercial Officer, Sterile and Generics

Key Stats

2.93 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

3.5K

2018

2.9K

2019

2.9K

2020(E)

2.7K
EPS (USD)

2017

3.840

2018

2.890

2019

2.380

2020(E)

2.123
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.42
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
2.61
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-0.92
Return on Equity (TTM)
-0.78

Latest News

Latest News

Endo starts manufacturing Novavax's potential COVID-19 vaccine

Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

BRIEF-U.S. FDA Approves Qwo™ (Collagenase Clostridium Histolyticum-Aaes), The First Injectable Treatment For Cellulite

* U.S. FDA APPROVES QWO™ (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES), THE FIRST INJECTABLE TREATMENT FOR CELLULITE

BRIEF-Endo International Announces Final Tender Results Of Previously Announced Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

BRIEF-Endo International Announces Final Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

New York charges Endo with insurance fraud over opioid claims

New York state filed civil charges on Wednesday accusing Endo International Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, adding fuel to the nation's opioid crisis.

New York charges Endo with insurance fraud over opioid claims

New York state filed civil charges on Wednesday accusing Endo International Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs.

BRIEF-Endo International PLC Announces Proposed Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES PROPOSED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

BRIEF-Endo International Reports Q1 EPS From Cont Ops Of $0.68

* Q1 DILUTED EPS FROM CONTINUING OPERATIONS 0.68 USD VERSUS 0.06 USD LOSS YEAR AGO

BRIEF-Endo Reports Q1 Adjusted Earnings Per Share $0.95

* ENDO REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE RELATING TO COVID-19 PANDEMIC

BRIEF-Endo International Says CEO Paul V. Campanelli's FY 2019 Total Compensation Was $13.1 Mln Vs $20 Mln In 2018

* ENDO INTERNATIONAL PLC SAYS CEO PAUL V. CAMPANELLI'S FY 2019 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $20 MILLION IN 2018 - SEC FILING

Endo beats Fresenius Kabi in antitrust fight over blood pressure drug Vasostrict

Fresenius Kabi USA LLC on Tuesday lost an antitrust lawsuit alleging a subsidiary of rival Endo International PLC used anticompetitive deals to keep generic versions of its blood pressure drug Vasostrict from hitting the market.

Drugmaker Endo beats profit view on sterile injectables unit strength

Drugmaker Endo International Plc <ENDP.O> on Wednesday posted a fourth-quarter profit that beat analysts' estimates, getting a boost from higher sales in its sterile injectables unit.

BRIEF-Endo Reports Q4 Loss Per Share Of $0.92 From Continuing Operations

* ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Drugmaker Endo posts smaller loss on asset impairment charges

Drugmaker Endo International Plc on Wednesday reported a smaller quarterly loss, due to a decrease in asset impairment charges.

BRIEF-Endo Appoints Mark G. Barberio To Board Of Directors

* ENDO APPOINTS MARK G. BARBERIO TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Endo International Says Blaise Coleman Entitled To Annual Base Salary Of $850,000

* ENDO INTERNATIONAL PLC - BLAISE COLEMAN IS ENTITLED TO AN ANNUAL BASE SALARY OF $850,000 Source: (https://bit.ly/3bSeFaI) Further company coverage:

BRIEF-Endo Names Blaise Coleman President And Chief Executive Officer

* ENDO NAMES BLAISE COLEMAN PRESIDENT AND CHIEF EXECUTIVE OFFICER

Judge upholds Endo patents on Adrenalin in loss for Pfizer generic unit

A judge on Thursday dealt a major setback to Pfizer Inc's Hospira in its bid to launch a generic version of Endo International plc's emergency allergy treatment Adrenalin.

Endo quarterly profit beat fueled by sterile injectables

Endo International Plc <ENDP.O> beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up